Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Indomethacin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 known ✓ | P35354 | 10/20 | 0.79 |
| ▸ | PTGS1 known ✓ | P23219 | 3/20 | 0.79 |
| ▸ | AKR1C3 | P42330 | 7/20 | 0.79 |
| ▸ | AKR1C2 | P52895 | 6/20 | 0.79 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.79 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.79 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.79 |
| ▸ | AKR1C4 | P17516 | 2/20 | 0.79 |
| ▸ | AKR1C1 | Q04828 | 2/20 | 0.79 |
| ▸ | LMNA | P02545 | 2/20 | 0.79 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.79 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.79 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.79 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.79 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.79 |
| ▸ | MEN1 | O00255 | 1/20 | 0.79 |
| ▸ | PTGES | O14684 | 1/20 | 0.79 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.79 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.79 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.79 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Indomethacin SCHEMBL11570993 | 1.00 | PTGS2 (0.79) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL1307338 | 0.92 | PTGS2 (0.75) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL4300161 | 0.90 | PTGS2 (0.74) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL29525957 | 0.89 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL29353712 | 0.89 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL3518614 | 0.89 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL9300 | 0.89 | PTGS2 (1.00) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL23391006 | 0.88 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL8352438 | 0.88 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A | |
| Indomethacin SCHEMBL1817813 | 0.88 | PTGS2 (0.98) | PTGS2AKR1C3AKR1C2PTGS1HIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0278977-A1 | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS. | BUNDGAARD HANS (DK) | 1988-08-24 | — | — | EP | claimed |
| WO-1988001615-A1 | PRODRUG DERIVATIVES OF CARBOXYLIC ACID DRUGS | BUNDGAARD HANS (DK) | 1988-03-10 | — | — | WO | claimed |
| US-12016764-B2 | Tubular implants with controlled biodegradation | POLY-MED, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| CN-111511310-B | Tubular implant with controlled biodegradation | 聚合-医药有限公司 | 2023-11-28 | — | — | CN | disclosed |
| US-20230255741-A1 | MEDICAL IMPLANTS HAVING MANAGED BIODEGRADATION | POLY-MED, INC. | 2023-08-17 | — | — | US | disclosed |
| EP-3979947-A1 | METHODS, DEVICES AND COMPOSITIONS FOR LOCAL DELIVERY | Poly-Med Inc. (US) | 2022-04-13 | — | — | EP | disclosed |
| US-20220071756-A1 | TUBULAR IMPLANTS WITH CONTROLLED BIODEGRADATION | POLY-MED, INC. | 2022-03-10 | — | — | US | disclosed |
| CN-114096213-A | Methods, devices and compositions for topical delivery | 聚合-医药有限公司 | 2022-02-25 | — | — | CN | disclosed |
| CN-109414331-B | Medical implant with managed biodegradation | 聚合-医药有限公司 | 2021-09-21 | — | — | CN | disclosed |
| EP-3752201-A1 | SUSPENSION OF NANOSCALE, ORGANIC PARTICLES AND PROCESS FOR PRODUCTION THEREOF | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-12-23 | — | — | EP | disclosed |
| WO-2020252077-A1 | METHODS, DEVICES AND COMPOSITIONS FOR LOCAL DELIVERY | POLY-MED, INC. (US) | 2020-12-17 | — | — | WO | disclosed |
| US-20090169471-A1 | PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2009-07-02 | — | — | US | disclosed |
| US-20090117039-A1 | CHARGED BIODEGRADABLE POLYMERS FOR MEDICAL APPLICATIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090092677-A1 | MULTI-COMPONENT PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2009-04-09 | — | — | US | disclosed |
| US-20090053276-A1 | INJECTABLE HYDROGEL COMPOSITIONS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008115543-A2 | UROLOGICAL MEDICAL DEVICES FOR RELEASE OF THERAPEUTIC AGENTS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| US-20080234659-A1 | UROLOGICAL MEDICAL DEVICES FOR RELEASE OF THERAPEUTIC AGENTS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| US-20080233167-A1 | UROLOGICAL MEDICAL DEVICES FOR RELEASE OF PROSTATICALLY BENEFICIAL THERAPEUTIC AGENTS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-09-25 | — | — | US | disclosed |
| WO-2008115536-A2 | UROLOGICAL MEDICAL DEVICES FOR RELEASE OF PROSTATICALLY BENEFICIAL THERAPEUTIC AGENTS | BOSTON SCIENTIFIC SCIMED, INC. (US) | 2008-09-25 | — | — | WO | disclosed |
| WO-1989008119-A1 | HIGH MOLECULAR WEIGHT PRODRUG DERIVATIVES OF ANTI-INFLAMMATORY DRUGS | SELCH LARSEN CLAUS (DK) | 1989-09-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090053276-A1 | INJECTABLE HYDROGEL COMPOSITIONS | DLST, MPST, USP1 | PTGS2 1651/4885PTGS1 1030/4885AKR1C3 4371/4885 |
| US-20090169471-A1 | PARTICLES FOR INJECTION AND PROCESSES FOR FORMING THE SAME | LPXN, PGF, NUP205 | PTGS2 384/4885PTGS1 285/4885AKR1C3 2788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.